Top

Clinical Research in Cardiology Supplements

Published in:

Open Access 01-06-2012

Lipid apheresis techniques: current status in Germany

Authors: Peter Grützmacher, Claudius Kleinert

Published in: Clinical Research in Cardiology Supplements | Special Issue 1/2012

Abstract

For long-term lipid apheresis therapy, several different technical systems have been developed which enable effective reduction of LDL cholesterol and other atherogenic lipoproteins, such as Lp(a), with sufficient selectivity and good clinical tolerance. Suitable techniques include whole blood adsorption with polyacrylamide and dextran sulfate cellulose, while primary plasma separation is used for cascade filtration, heparin-induced precipitation, immunoadsorption, silicate gel adsorption, and dextran sulfate cellulose (both techniques).

The technical features are described. Only intensive training and experience of the medical personnel guarantees reliable treatment safety of all systems at a very low rate of minor side effects.

Bosch T, Lennertz A, Schenzle D, Dräger J (2002). Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J Clin Apheresis 17:161–169PubMedCrossRef

Fridey JL, Kaplan AA (2009) Prescription and technique of plasma exchange uptodate-online 2009

Heibges A, Fassbender C, Klingel R (2010) Akt. Praxis der Lipidapherese, Nieren- und Hochdruckkrankheiten 39:322–337

Klingel R, Fassbender R, Fassbender C, Göhlen B (2003) From membrane differential filtration to lipid filtration: technological progress in low-density lipoprotein apheresis. Ther Apher Dial 7:350–358PubMedCrossRef

Messner H, Godehardt E, Köbberling J, Hein D (1993) Membrane diffetential filtration in extracorporeal LDL-cholesterol elimination. In: Gotto AM, Mancini M, Richter WO, Schwandt P (eds) Treatment of servere dyslipoproteinemia in the prevention of coronary heart disease. Basel, Karger, pp 204–207

Richter WO, Donner MG, Hofling B, Schwandt P (1998) Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 47:863–868PubMedCrossRef

Parhofer KG (2010) Dyslipoproteinämien—Strategien zur Diagnostik und Therapie, 3. Aufl. Uni-MED-Verlag, Bremen

Rosenson RS (2011) Treatment of drug-resistant hypercholesterolemia uptodate-online 2011

Schuff-Werner P (2001) Diagnostik und Therapie der Dyslipoproteinämien—Heparin-induzierte extrakorporale LDL-Präzipitation (HELP). In: Schwandt P, Richter WO, Parhofer KG (eds) Handbuch der Fettstoffwechselstörungen. Schattauer, Stuttgart, pp 538–556

10.

Schuff-Werner P, Gohlke H, Bartmann U (1994) The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest 24:724–732PubMedCrossRef

11.

Schwandt P, Parhofer KG (2007) Handbuch der Fettstoffwechselstörungen, 3 edn. Schattauer Verlag

12.

Seidel D (1994) HELP report—10 years of clinical experience. MMV Medizin Verlag, München

13.

Thompson GR, Maher VM, Matthews S et al (1995) Familial hypercholesterolemia regression study: a randomized trial of low-density-lipoprotein apheresis. Lancet 345:811–816PubMedCrossRef

14.

Thompson GR (2008) HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 198(2):247–255PubMedCrossRef

15.

Thompson GR (2003) LDL apheresis. Atherosclerosis 167(1):1–13PubMedCrossRef

16.

Wendler T, Schilling R, Lennertz A, Sodemann K, Kleophas W, Meßner H, Riechers G, Wagner J, Keller C, Bosch T (2003) Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study. J Clin Apheresis 18:157–166PubMedCrossRef

Title: Lipid apheresis techniques: current status in Germany
Authors: Peter Grützmacher
Claudius Kleinert
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Clinical Research in Cardiology Supplements / Issue Special Issue 1/2012
Print ISSN: 1861-0706
Electronic ISSN: 1861-0714
DOI: https://doi.org/10.1007/s11789-012-0047-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Lipid apheresis techniques: current status in Germany

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2012

Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss

Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis

Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R)

Current view: indications for extracorporeal lipid apheresis treatment

Editorial

Lipid apheresis: oxidative stress, rheology, and vasodilatation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page